论文部分内容阅读
在几个高心血管发病风险人群,血管紧张素转化酶抑制剂或血管紧张素受体拮抗剂可以不通过降低肱动脉收缩压或舒张压而降低患者心血管病的发病率和死亡率。这一现象是否由通常低于肱动脉收缩压的中心动脉收缩压明显下降所致目前还没有相关研究。本研究旨在了解小剂量血管紧张素转换酶抑制剂培哚普利(Per)和利尿剂吲达帕胺(Ind)联合用药是否比β-受体阻滞剂阿替洛尔更有效降低中心动脉(胸主动脉、颈动脉)及肱动脉收缩压,并了解独立影响肱动脉和中心动脉收缩压的血液动力学因素:脉搏波传导速度(PWV)和波反射的方式。
In several people at high cardiovascular risk, ACE inhibitors or angiotensin receptor blockade may reduce the incidence and mortality of cardiovascular disease in patients without reducing brachial artery systolic or diastolic blood pressure. Whether this phenomenon is caused by the marked decrease of systolic pressure of the central artery, which is usually lower than the systolic pressure of the brachial artery, has not been studied yet. This study aimed to understand whether the combination of a low dose of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide (Ind) is more effective in lowering the center than the beta-blocker atenolol Arterial (thoracic aorta, carotid artery) and brachial artery systolic pressure and to understand the hemodynamic factors that independently affect the brachial and central systolic blood pressure: pulse wave velocity (PWV) and wave reflex.